异动解读 | 药明合联收购要约正式生效,东曜药业-B盘中大涨11.09%

异动解读
Mar 20

东曜药业-B今日盘中大涨11.09%,引起了市场的广泛关注。

消息面上,药明合联对东曜药业的现金要约收购已取得东曜药业60%股权之有效接纳,股份要约已正式生效。通过本次控股收购,药明合联将进一步丰富项目组合、扩大客户群体,增强产能配置,持续稳固在全球ADC CRDMO领域的领先地位。

根据香港联交所披露的文件,WuXi XDC Cayman Inc.以每股均价4.0港元场外增持东曜药业4.64亿股普通股股份,价值约18.55亿港元。增持后,其最新持股数目为4.64亿股股份,好仓比例由0.00%大幅升至60.00%。市场认为,此次收购的顺利推进和控股权的确立,是推动股价上涨的主要动力。

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10